Allscripts Healthcare Solutions (MDRX) Rating Lowered to Hold at BidaskClub

Allscripts Healthcare Solutions (NASDAQ:MDRX) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Friday.

Several other research analysts have also issued reports on the company. Evercore ISI assumed coverage on Allscripts Healthcare Solutions in a research report on Thursday. They issued an “outperform” rating and a $17.50 target price for the company. SunTrust Banks lowered Allscripts Healthcare Solutions from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. They noted that the move was a valuation call. Zacks Investment Research lowered Allscripts Healthcare Solutions from a “hold” rating to a “sell” rating in a research report on Friday, January 12th. Royal Bank of Canada set a $19.00 target price on Allscripts Healthcare Solutions and gave the stock a “buy” rating in a research report on Thursday, January 11th. Finally, Maxim Group reissued a “buy” rating and issued a $20.00 target price on shares of Allscripts Healthcare Solutions in a research report on Tuesday, January 9th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $15.66.

Shares of Allscripts Healthcare Solutions (NASDAQ:MDRX) traded up $0.15 during trading hours on Friday, hitting $15.24. The stock had a trading volume of 1,401,766 shares, compared to its average volume of 1,432,528. Allscripts Healthcare Solutions has a 12-month low of $11.01 and a 12-month high of $16.12. The company has a market cap of $2,753.58, a price-to-earnings ratio of 35.44, a P/E/G ratio of 2.15 and a beta of 1.33. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.98 and a quick ratio of 0.98.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last announced its earnings results on Thursday, November 2nd. The software maker reported $0.12 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.12. Allscripts Healthcare Solutions had a positive return on equity of 6.53% and a negative net margin of 12.23%. analysts forecast that Allscripts Healthcare Solutions will post 0.46 earnings per share for the current fiscal year.

In other Allscripts Healthcare Solutions news, President Richard J. Poulton sold 15,000 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $14.26, for a total transaction of $213,900.00. Following the sale, the president now directly owns 1,351,773 shares in the company, valued at approximately $19,276,282.98. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP James Hewitt sold 36,796 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $14.11, for a total value of $519,191.56. Following the sale, the senior vice president now owns 181,766 shares in the company, valued at $2,564,718.26. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,796 shares of company stock valued at $804,842. 0.75% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Fuller & Thaler Asset Management Inc. boosted its stake in Allscripts Healthcare Solutions by 1.0% during the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 5,062,035 shares of the software maker’s stock valued at $72,033,000 after purchasing an additional 49,823 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Allscripts Healthcare Solutions by 26.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 9,171,285 shares of the software maker’s stock valued at $117,026,000 after purchasing an additional 1,943,496 shares during the last quarter. Royal Bank of Canada boosted its stake in Allscripts Healthcare Solutions by 53.3% during the 2nd quarter. Royal Bank of Canada now owns 955,183 shares of the software maker’s stock valued at $12,189,000 after purchasing an additional 331,967 shares during the last quarter. Vanguard Group Inc. boosted its stake in Allscripts Healthcare Solutions by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 14,824,640 shares of the software maker’s stock valued at $189,162,000 after purchasing an additional 181,721 shares during the last quarter. Finally, Ameritas Investment Partners Inc. boosted its stake in Allscripts Healthcare Solutions by 30.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 69,163 shares of the software maker’s stock valued at $883,000 after purchasing an additional 15,950 shares during the last quarter.

TRADEMARK VIOLATION WARNING: This story was reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/21/allscripts-healthcare-solutions-mdrx-rating-lowered-to-hold-at-bidaskclub.html.

Allscripts Healthcare Solutions Company Profile

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Analyst Recommendations for Allscripts Healthcare Solutions (NASDAQ:MDRX)

Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply